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Autopsy information on cardiovascular damage was investigated for pathologically conﬁrmed Alzheimer disease (AD) patients
(n = 84) and non-AD control patients (n = 60). The 51 relevant items were entered into a grade-of-membership model to de-
scribe vascular damage in AD. Five latent groups were identiﬁed “I: early-onset AD,” “II: controls, cancer,” “III: controls, extensive
atherosclerosis,” “IV: late-onset AD, male,” and “V: late-onset AD, female.” Expectedly, Groups IV and V had elevated APOE 4
frequency. Unexpectedly, there was limited atherosclerosis and frequent myocardial valve and ventricular damage. The ﬁndings do
not indicate a strong relationship between atherosclerosis and AD, although both are associated with the APOE 4. Instead, autopsy
ﬁndings of extensive atherosclerosis were associated with possible, not probable or deﬁnite AD, and premature death. They are con-
sistent with the hypothesis that brain hypoperfusion contributes to dementia, possibly to AD pathogenesis, and raise the possibility
that the APOE allele 4 contributes directly to heart valve and myocardial damage.
INTRODUCTION
It is well known that Alzheimer’s disease (AD) is the
most common form of senile dementia in the US and
Europe. Population studies suggest that 47% of persons
over age 85 are aﬀected [1, 2, 3]. The established ge-
netic risk factor is the E4 isoform for the lipid transport
molecule apolipoprotein E (APOE: gene; ApoE: protein)
[4, 5, 6, 7, 8, 9, 10] which is also a risk factor for coronary
atherosclerosis [11, 12, 13, 14, 15, 16, 17, 18, 19]. The 4
allele for APOE has sometimes been implicated in vascu-
lar dementia (VaD) and stroke [20, 21, 22], the second
most common form of senile dementia.
Previous studies have shown decreased smooth mus-
cle actin in brain blood vessels of AD patients when com-
pared to nondemented controls [23]. Possibly, more ex-
tensive amyloid deposition in heart and brain vessels de-
termines the 5-fold worse prognosis (8% compared to
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40%mortality)withinthreemonthsfollowingadiagnosis
of heart disease or stroke at ages 85+ for 3/4+ persons,
compared to 2/3+ [24], and largely accounts for reduced
4, and elevated 2, frequencies found among centenari-
ans [25].
Theroleofcardiovasculardamageinthedevelopment
of AD is consistent with a number of existing reports
in the literature, although few deal with pathologically
conﬁrmed AD and pathologic cardiovascular ﬁndings in
age-matchedsamples.Certainly,cardiovasculardamageis
common among subjects with neuropathologically con-
ﬁrmed AD [26, 27]. Hypertension has been suggested as a
risk factor for subsequent AD, normal or low blood pres-
sure at the end stages of the disease [28, 29, 30, 31, 32].
Skoog et al [31] investigated a population cohort and
found an association between elevated blood pressure at
age 70 years and the development of dementia 10 to 15
years later. They hypothesized that hypertension causes
hyalinization of the vessel walls in the brain and hypop-
erfusion in the deep white matter.
Atherosclerotic disease and silent myocardial infarcts
have been associated with cognitive impairment [26, 27].
In the Rotterdam study [33], the extent of atherosclero-
sis was assessed by ultrasonography of the carotid arteries
and by the ratio of ankle to brachial systolic blood pres-
s u r e .S u b j e c t sw e r es c o r e df r o m0t o3 ,f r o mn ot os e -
vere, atherosclerosis. The odds of a clinical AD diagnosis190 Elizabeth H. Corder et al 2005:2 (2005)
increased 2-fold with the extent of atherosclerosis, 3-fold
for VaD.
Autopsy studies are limited, but suggest that cardio-
vascular disease contributes to the expression of demen-
tia for patients who exhibit Alzheimer neuropathologic
changes. Sparks et al [28] showed that signiﬁcant coro-
nary artery disease was present in 90% (19 of 21) of
AD patients undergoing a complete postmortem exam-
ination. Patients with peripheral vascular disease, cere-
brovascular accidents, and myocardial infarcts had lower
antemortem cognitive scores on the minimental state
exam [27]. Patients with end-stage renal disease have cog-
nitive impairment thought to be due to multiinfarct de-
mentia [34].
However, Irina et al [35] did not ﬁnd a correla-
tion of dementia or pathologically conﬁrmed AD with
pathologic cardiovascular index (CVI), that is, the extent
of atherosclerosis in the brain and periphery combined
with evidence of cardiovascular lesions and cardiomegaly.
Speciﬁcally, the CVI was higher for 103 nondemented
subjects compared to 106 demented subjects, 9.2 versus
7 . 5o u to fap o s s i b l e1 5( P<. 05). Mean CVI was 5.2 for
subjects meeting CERAD criteria for possible AD, 7.3 for
deﬁnite AD, increasing to 8.5 for vascular and mixed de-
mentia.ThusatherosclerosiswasassociatedwithVaD,not
the extent of Alzheimer’s lesions (associated with the 4
allele for APOE).
To clarify the role of cardiovascular disease in demen-
tia, we investigated 144 subjects prospectively enrolled in
the Bryan Alzheimer Disease Research Center Rapid Au-
topsy Program at Duke University who had had complete
body autopsies.
METHODS
Therapidautopsyprogram
The Rapid Autopsy Program of the Bryan Alzheimer
Disease Research Center has been in continuous exis-
tence since 1985 [36]. Recruitment, enrollment, and au-
topsy procedures have been approved by the Institu-
tional Review Board. After receiving informed consent
from the patients and their families, both demented and
nondemented control donors are enrolled and followed
prospectively until death. While the principal purpose of
the program is to retrieve and bank human brain tis-
sue for use in research, many donors have consented to
complete diagnostic autopsy. At the time of death, con-
sent for autopsy is again obtained according to Duke Uni-
versity Medical Center regulations. Autopsy is performed
in the usual fashion with examination of all body or-
gans and cavities. Autopsies are performed in compliance
with Centers for Disease Control precautions against the
spread of infectious diseases [37, 38].
Dataabstraction
APOE genotype (for 46 demented and 38 nonde-
mented subjects) was obtained from existing databases.
We abstracted the 144 autopsy records to obtain informa-
tion on dementia status, cardiovascular disease, medical
diagnoses, and organ weights. An Excel spreadsheet was
used as the abstract form. Abstraction was done indepen-
dently by two persons. Inconsistencies were resolved by
consensus among the authors. The 51 items are listed in
Tables 1–3,r e s p e c t i v e l y .
Thestatisticalapproach
Detailed clinical proﬁles were identiﬁed using a sta-
tistical technique called grade-of-membership analysis or
GoM [39, 40]. Use of univariate approaches would nec-
essarily have low power at this sample size, especially if
corrected for multiple comparisons (not needed when all
variables are jointly examined). An additional advantage
is that each variable can be understood in relation to all
the other variables allowing a clinical narrative, some-
thing like the process of diagnosis, to be achieved for the
identiﬁed latent model-based groups.
GoM can be described after ﬁrst identifying four in-
dices. One is the number of subjects I (i = 1,2,...,I).
Here I = 144 subjects were identiﬁed. The second index
is the number of variables J (j = 1,2,...,J). There are
J = 50 variables each representing one of the clinical vari-
ables described above. Our third index is Lj: the set of
response levels for the Jth variable.
This leads to the deﬁnition of the basic GoM model
wheretheprobabilitythattheithsubjecthastheLjthlevel
of the Jth variable is deﬁned by a binary variable (ie, yijl =
0,1). The model with these deﬁnitions is
Prob

yijl = 1.0

=

k
gikλkjl, (1)
where the gik are convexly constrained scores (ie, 0.0 ≤
gik ≤ 1.0;

k gik = 1.0 ) for subjects and the λkjlare prob-
abilities that, for the Kth latent group, the Ljth level is
found for the Jth variable. The procedure thus uses this
expression to identify K proﬁles representing the pattern
of J × Ljresponses found for I subjects.
The parameters gik and λkjl are estimated simulta-
neously using the likelihood function (in its most basic
form) [39, 40].
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In the likelihood yijl is 1.0 if the Ljth level is present
and 0.0 if it is not present. GoM models specifying from
K = 3–5 groups, that is, clinical proﬁles, were con-
structed. The signiﬁcance of adding the K + 1 proﬁle was
tested as an independent increment in the ﬁt of the model
adjusting for the larger number of degrees of freedom in
the larger model. Akaike information criterion [41]w a s
calculated as
AIC =− 2l
 θ

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Table 1. The clinical variables.
No Variable Description
1 Dementia 0 = no, 1 = yes (ie, age at onset listed)
2 Dementia status
0 = normal, 1 = dementia, 2 = normal cognition,
3 = disease control, 4 = early dementia,
6 = Parkinson’s disease (PD)
3 Final diagnosis 0 = normal, 1 = AD, 2 = PD, 3 = possible AD, 4 = not listed
4A g e a t o n s e t 0 = not demented, 1≤60 years of age, 2 = 60–70, 3 = 70–80, 4 = 80+
5 Duration of dementia 0 = normal, 1 ≤ 5 years, 2 = 5–10, 3 = 10–15, 4 = 15+
6 Age at death 1 ≤ 60 years, 2 = 60–70, 3 = 70–80, 4 = 80+
7S e x 0 = male, 1 = female
8R a c e 0 = white, 1 = black
9 Body mass index 0 = 8–17.9, 1 = 17.9–21.2, 2 = 21.2–25.0, 3 = 25+, 9 = missing
10 Cancer diagnosis 0 = no, 1 = yes
11 Respiratory system infection 0 = no, 1 = yes
12 Urinary system infection 0 = no, 1 = yes
13 Digestive system infection 0 = no, 1 = yes
14 APOE genotype 0 = 22, 1 = 23, 2 = 33, 3 = 24, 4 = 34, 5 = 44
where l is the likelihood value and P is the number of
estimated parameters. However, for parameters on the
boundary, that is, value = 0, only one is penalized. The
rationale for subtracting only one for parameters on the
boundary is that the distribution for those parameters
is (1/2)X2 (central). The lowest value of the AIC desig-
nates the best model, that is, the model with the best
ﬁt and least bias. GoM models specifying either 3, 4, 5,
or 6 clinical proﬁles, that is, K = 3–6, had AIC =
−1503,−1647,−1703, and −1678, respectively. The 5-
group model is reported.
Information on APOE genotype was not used to con-
struct the groups used to clinically characterize the sub-
jects. One option in the likelihood is to separate calcula-
tions for “internal” (here, clinical) and “external” (here,
APOE genotype) variables. For internal variables, MLE of
gik and λkjl are generated and the information in internal
variables is used to deﬁne the K groups. For external vari-
ables the likelihood is evaluated (and MLE of λkjl; gener-
ated) but the information is not used to redeﬁne the K
groups, that is, the likelihood calculations for likelihood
equations involving the gik are disabled for external vari-
ables so that the gik, and the deﬁnition of the K groups, is
not changed.
RESULTS
Overview
Five model-based groups best represented the autopsy
information on diagnoses, cardiovascular disease, and or-
gan weights. They are labeled I, II, III, IV, and V ordered
according to increasing age at the time of death. Each
group is deﬁned by the probabilities of response for the
many variables, akin to the frequencies found in the sam-
ple as a whole. Tables 4–6 describe the proﬁles in terms
of diagnoses, cardiovascular damage, and organ weights,
respectively. Not all the variables described in Tables 1–3
are shown in the tables of results.
The size of the groups was similar (Table 4). The sizes
are the summed memberships of individuals in the re-
spective groups either partial, that is, fractional, or com-
plete, that is, contributing size one to the sum, depend-
ing on the extent of resemblance of the individual to the
group. Group I was the largest group (n = 36.4) and
Group II was the smallest (n = 21.3). The prevalence
of demented and nondemented subjects, that is, sum of
memberships, in each model-based group is shown in
Table 7, as well as the distribution of APOE frequencies
across the model-based groups.
Dementiadiagnoses
Next observe that the groups were either demented or
not demented (Table 4): Groups I, IV, and V had 100%
probability of dementia while Groups II and III were not
demented. There was high probability that dementia was
speciﬁcally due to AD: 81% for Group I, 73% for Group
IV,and72%forGroupV.Otherwise,noexplanatorydiag-
nosis was given for the dementia for these groups. Groups
II and III had no chance of an AD diagnosis. However,
possible AD was sometimes found in the nondemented
groups, 9% for Group II and 43% for Group III (5–10
y e a r sy o u n g e rt h a nG r o u p sI Va n dV ) .G r o u pI Ih a da
22% chance of being a so-called “disease control” and
GroupIIIhada10%chanceofhavingParkinson’sdisease.
T h ed e m e n t i as t a t u sa n dﬁ n a ld i a g n o s e sv a r i a b l e sa r ed e -
scribed in Table 2.
Onsetage,sex,anddementiaduration
As the age at the onset of dementia for Group I
was usually before age 65, Group I represents early-onset
AD. Groups IV (male) and V (female) represent late-192 Elizabeth H. Corder et al 2005:2 (2005)
Table 2. The cardiovascular variables.
No Variable Description
15 Pericardial cavity ﬂuid 0 ≤ 10mL, 1 = 11–50, 2 = 51–100, 3≥100, 9 = missing
16 Right pleural cavity ﬂuid 0 ≤ 10mL, 1 = 11–50, 2 = 51–100, 3 ≥ 100, 9 = missing
17 Left pleural cavity ﬂuid 0 ≤ 50mL, 1 = 51–200, 2 = 201–500, 3 ≥ 500, 9 = missing
18 Peritonial ﬂuid 0 ≤ 50mL, 1 = 51–200, 2 = 201–500, 3 ≥ 500, 9 = missing
19 Aorta atherosclerosis 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
20 Right coronary artery atherosclerosis 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
21 Right coronary artery narrowing 0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
22 Right coronary artery calciﬁcation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
23 Left main coronary artery atherosclerosis 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
24 Left main coronary artery narrowing 0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
25 Left main coronary artery calciﬁcation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
26 Circumﬂex branch atherosclerosis 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
27 Circumﬂex branch narrowing 0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
28 Circumﬂex branch calciﬁcation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
29 Anterior descending branch atherosclerosis 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
30 Anterior descending branch narrowing 0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
31 Anterior descending branch calciﬁcation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
32 Right atrial cavity dilation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
33 Right atrial wall thickness 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
34 Right ventricular cavity dilation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
35 Right ventricular wall thickness 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
36 Left atrial cavity dilation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
37 Left atrial wall thickness 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
38 Right ventricular cavity dilation 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
39 Right ventricular wall thickness 0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
40 Aortic valve 0 = normal, 1 = abnormal, 9 = missing
41 Tricuspid valve 0 = normal, 1 = abnormal, 9 = missing
42 Pulmonic valve 0 = normal,1 = abnormal, 9 = missing
43 Mitral valve 0 = normal, 1 = abnormal, 9 = missing
44 Ventricular myocardium 0 = normal, 1 = abnormal, 9 = missing
Table 3. The quartiles for organ weights.
No Variable Description
45 Heart 0 ≤ 295gm, 1 = 295–351, 2 = 351–412, 3 = 412+, 9 = missing
46 Lungs (mean) 0 ≤ 316gm, 1 = 316–443, 2 = 443–585, 3 = 585+, 9 = missing
47 Liver 0 ≤ 880gm, 1 = 880–1100, 2 = 1100–1140, 3 = 1140+, 9 = missing
48 Kidneys (mean) 0 ≤ 99gm, 1 = 99–125, 2 = 125–153, 3 = 153+, 9 = missing
49 Spleen 0 ≤ 75gm, 1 = 75–113, 2 = 113–170, 3 = 170+, 9 = missing
50 Adrenals (mean) 0 ≤ 6.95gm, 1 = 6.95–8.1, 2 = 8.1–10.2, 3 = 10.2+, 9 = missing
51 Thyroid 0 ≤ 9.25gm, 1 = 9.25–14, 2 = 14–20, 3 = 20+, 9 = missing
onset AD: the mean age at onset was around 70 years
of age for both groups, marginally earlier for female
Group V compared to male Group IV. Nonetheless Group
V had longer disease duration and an older age at the
time of death. The 2% of the sample that was black
was concentrated in the control Groups II and III (not
shown).
BMIandnonneurologicdiagnoses
Early-onset dementia (I) was associated with ex-
tremely low body mass index (BMI). Women with late-
onset dementia and long dementia duration (V) also had
very BMI. Cancer was a common diagnosis for Group II,
absent for Group III. Men with late onset dementia also
frequently had cancer (IV), absent for female Group V.2005:2 (2005) Heart Disease and AD 193
Table 4. Clinical variable frequencies for each group. Each model-based group is deﬁned by the probabilities of being demented &
probabilities of response for the other variables, that is, the model λ parameters.
Variable Response
Group
N = 36.4 N = 21.3 N = 27.2 N = 27.5 N = 31.5
II I I I I I V V
Demented Yes (%) 100 0 0 100 100
Age at onset
< 60 years 81 — — 7 0
60–70 15 — — 35 53
70–80 4 — — 46 34
80+ 0 — — 12 13
Duration of dementia
< 5 years 12 — — 5 0
5–10 38 — — 62 0
10–15 43 — — 33 37
15+ 7 — — 0 63
Age at death
< 60 20 20 0 0 0
60–70 73 0 12 0 0
70–80 7 73 68 31 12
80+ 0 7 20 69 88
S e x F e m a l e 6 62 03 5 01 0 0
BMI (km/m2)
8–17.9 67 0 0 4 23
17.9–21.2 11 0 0 37 54
21.2–25.0 13 41 17 51 14
25+ 10 59 83 9 9
Cancer diagnosis Yes 24 84 0 60 0
Respiratory infection Yes 69 70 82 57 100
Urinary tract infection Yes 16 16 27 29 44
Digestive tract infection Yes 20 0 22 30 54
Respiratoryandurinaryinfectionswerecommonforeach
groupespeciallyfordementedwomen(V).Digestivetract
infections were not found for Group II (cancer).
Cardiovasculardisease
There was little evidence of cardiovascular disease for
the early-onset relatively young Group I. Control Group
II with cancer uniquely often had pulmonary eﬀusions,
ascites, and a moderately dilated right ventricle. Groups
II–V had minimal amounts of pericardial cavity ﬂuid, ab-
sent for Group I (not shown).
Control Group III without cancer had severe
atherosclerosis with narrowing and calciﬁcation in the
aorta and each of the major coronary vessels—right coro-
nary artery, left main coronary artery, circumﬂex branch,
and anterior descending branch. The extent of atherscle-
rosis was usually similar for each vessel. Table 5 represents
the average over all the coronary vessels. Group III with
extensiveatherosclerosisoftenalsohadmoderateatrialdi-
lation and moderately thickened ventricular myocardium
(not shown).
Atherosclerosiswasunexpectedlylessextensiveforde-
mentedGroupsIVandV,limitedforGroupII,andabsent
for Group I.
Aortic and mitral valve damage and evidence of is-
chemic damage to the left ventricular myocardium were
common for male late-onset dementia Group IV, and
also female Group V. Both of the late-onset dementia
groups and Group III had a moderately dilated right
atrium.
Organweights
Generally speaking, the organ weights shown in
Table 6 paralleled the BMI results shown in Table 4.
Nonetheless there were some interesting departures: or-
gan weights were preserved for Group I having the lowest
BMI. The low heart weight for this relatively young group
is consistent with limited heart damage, as indicated by
Table 4. Lung weight was highest for Group II, which of-
ten had pulmonary edema and pleural eﬀusions. Group
III, most aﬀected by atherosclerosis, had the highest heart
weight. Compared to Group III, organ weights and BMI
were lower for Group IV. Very low BMI and weight for
most organs was found for late-onset dementia Group V,
females with long dementia duration. Notably, both late-
onset dementia groups had low thyroid weight compared
to the early-onset and control groups.194 Elizabeth H. Corder et al 2005:2 (2005)
Table 5. Cardiovascular damage for each group. The model-based groups are deﬁned by the probabilities response for the variables
sometimes represented on a semiquantitative scale: “+++” denotes severe, while “++,” “+,” and “−” denote moderate, mild, and the
absence of lesions; “+ + /−” denotes mixture of moderate and absent; “+/−” denotes mixture of mild and absent; “+ + /+” denotes
a mixture of moderate and mild; “+ + +/−” denotes a mixture of severe and absent. ∗means the average of right coronary artery, left
main coronary artery, circumﬂex branch, and anterior descending branch.
Outcome Location
Group
I II III IV V
Fluid
Peritoneal cavity − +++/− +/−− −
Pleural cavity − +++ +/−− −
Coronary artery∗
Atherosclerosis − +/− +++ ++ +
Narrowing − +/− +++ ++ +
Calciﬁcation − +/− +++ ++ +
Aorta Atherosclerosis +/− ++ +++ ++ ++/+
Dilation
Right atrium − +/− ++/− ++ ++
Right ventricle +/− ++/− +/− ++
Left atrium − +/− +/− +/− +/−
Left ventricle +/− ++ − +/−
Damage
Aortic valve — 20 — 100 33
Mitral valve 14 32 — 100 45
Pulmonic valve — — — 37 14
Tricuspid valve — 19 3 64 17
Ventricular myocardium — — — 49 46
APOEgenotype
APOE genotype data was available on a subset of 84
subjects, 46 with dementia and 38 controls. Although this
information was not used to predict the groups, individ-
uals carrying the 4a l l e l ew e r em o r ec o m m o ni nt h ed e -
mentia groups. The summed memberships of individuals
of each genotype are shown in Table 7. As individuals, the
study subjects who exactly resembled a single proﬁle con-
tributed one to the size of the relevant proﬁle and zero
to the other proﬁles. Otherwise, the subject contributed a
total of one to the sizes of the relevant proﬁles depending
on the extent of resemblance. In contrast to results, Tables
4– 6 that predict frequencies for persons exactly like the
group, Table 7 demonstrates that as individuals there was
overlap of demented and nondemented subjects in the
groups, not surprisingly given the many variables used to
construct the groups, frequent comorbidity at advanced
ages, and diﬀerences from individual to individual.
DISCUSSION
We investigated cardiovascular damage found for 84
demented and 60 nondemented subjects enrolled in the
Bryan ADRC Rapid Autopsy Program. The subjects could
be represented by ﬁve distinct latent groups based on de-
tailed pathologic information. The late-onset AD groups,
both male (IV) and female (V), had frequent heart valve
damage, evidence of ischemic damage to the left ventric-
ular myocardium, low BMI, and low organ weights no-
tably including the thyroid gland. They did not have ex-
tensive atherosclerosis compared to control subjects with-
out cancer (III), many of whom had possible AD. In par-
ticular, the female group (V) having long AD duration
hadlittleatherosclerosis.Controlsubjectswithcancer(II)
had little atherosclerosis or valve damage. Instead, pul-
monaryedemaandasciteswerecommon.Theearly-onset
AD group (I) had little cardiovascular damage, with nor-
mal organ weights despite low body weight.
The ﬁnding of mitral and aortic valve damage, and
evidence of ischemic damage to the left ventricular my-
ocardium for the AD groups, especially among men, is
interesting. It is consistent with the hypothesis that brain
hypoperfusion and microthrombi may contribute to the
evolution of AD pathology or to the expression of demen-
tia at an earlier stage in AD pathogenesis [40].
However, the AD groups (IV and V) were the old-
est groups. Thus valve and myocardial damage might
simply be age related and less rapidly fatal than exten-
sive coronary atherosclerosis. Alternatively, the oldest co-
horts in the sample may have valve damage resulting from
rheumatic fever not treated with antibiotics. Assuming
that mitral valve damage is related to rheumatic fever in
the oldest subjects does not, however, rule out the possi-
bility that it contributes to the expression of dementia by
decreasing brain perfusion and, possibly, contributing to
brain pathology.
In addition, the lack of an age-matched control group
requires comment. Since aging is itself a risk factor for
valvular disease, an age-matched control group would be2005:2 (2005) Heart Disease and AD 195
Table 6. Organ weights for each group. The model-based groups are deﬁned by the probabilities response for the variables, here
represented on a semiquantitative scale: “+ + ++” denotes the highest quartile of weight, while “+ + +,” “++,” and “+” denote the
respectively lower quartiles.
Organ Group
I II III IV V
Heart + +++ ++++ +++ ++
Lungs ++ ++++ +++ ++ +
Liver +++ ++++ ++++ +++ +
Kidneys +++ +++ ++++ +++ +
Spleen ++ ++++ ++++ ++ +
Adrenals +++ ++++ +++ +++ +
Thyroid +++ ++++ ++++ +++ +
Table 7. Distribution of subjects across the groups, subdivided according to dementia status and APOE genotype; 2/2a n d/2/3
were grouped with 3/3; 2/4a n d4/4w e r eg r o u p e dw i t h3/4. The sizes are the sums of the model gik parameters, that is, the
memberships of individuals in the groups, whole or partial.
Subjects Group
II I I I I I V V A l l
Demented 30.9 2.3 8.5 19.7 22.6 84
Not demented 5.5 19.0 18.7 7.8 9.0 60
3/3+ Demented 4.0 0 2.0 3.9 5.0 15
Normal 2.4 9.1 8.6 2.2 3.6 26
4/4 Demented 12.3 1.0 3.2 8.2 6.2 31
Normal 1.6 3.5 3.8 1.5 1.5 11
Total 36.4 21.3 27.2 27.5 31.5 144
required to fully examine the hypothesis that hypoper-
fusion contributes to dementia. Unfortunately, this was
notpossibleinthissmall-human-population-basedstudy.
Rigorous analysis must await examination of a larger co-
hort.
Despite the caveats, the results on valve and myocar-
dial damage are striking and the given frequent ﬁnding of
the 4a l l e l ef o rAPOE in the AD groups raises the pos-
sibility that ApoE directly damages these structures as it
has been demonstrated to damage blood vessels [42, 43].
Muscle actin in the arterioles is replaced by amyloid for
4/4+ subjects to a much greater extent than for 3/3+
subjects. Meyer et al [44]( n = 36) found hypertrophy of
theleftventricle(uncommonintheBryanADRCsample)
i n9o f1 9( 4 7 % )3/4+ AD patients and only 1 of 11 (9%)
3/3+ patients (χ22 = 3.8, df = 1, P = 0.05). There were
no statistically signiﬁcant diﬀerences in the presence of
stenotic changes or calciﬁcation in aortic or mitral valvu-
lae in this small sample. The study results tend to suggest
that the 5-fold worse prognosis following a diagnosis of
heart disease or stroke at ages 85+ for 4+ persons may
be due to impaired cerebrovascular function due to amy-
loid deposition [25]. Data presented here would also sug-
gest that cardiovascular malfunction may be a contribut-
ing factor.
The study does not support the notion that extensive
atherosclerosis is a risk factor for deﬁnite AD. Instead,
subjects with extensive atherosclerosis died before a di-
agnosis of probable or deﬁnite AD could be made. The
relatively low 4 frequency for control subjects with ex-
tensive atherosclerosiswasunexpectedsincetheallelecar-
ries a modestly increased risk of coronary atherosclerosis
[13, 14, 15, 16, 17, 44]. There is also a small ecologic as-
sociation between 4 frequency and population rates of
myocardial infarction in middle age [45, 46]. Neverthe-
less the ﬁndings from this study are consistent with the
lack of risk for heart disease and stroke for 4 found in
the Kungsholmen Project for cohort age of 75 and older
[25].
Atherosclerosis may possibly at least partially reverse
itself during the clinical progression of AD as weight
is lost and food intake diminished. This explanation is
supported to some extent by the fact that possible AD
was common in the nondemented group with high heart
weight and extensive atherosclerosis. So thatatherosclero-
sismightbeacommonconcomitantofearlyorpreclinical
AD but may not be found at the time of death many years
later.
A strong feature of the study is that comparisons
were made based on pathologic features and patholog-
ically conﬁrmed diagnoses. The data analytic approach
was helpful in resolving the many items of information
into a tractable number of distinct groups consistent with
clinical experience, despite the relatively small sample196 Elizabeth H. Corder et al 2005:2 (2005)
size. For example, heart weight was highest for the group
also having the most extensive athersosclerosis and lung
weight was highest for the group also having pulmonary
eﬀusions and ascites.
In summary, extensive coronary atherosclerosis at au-
topsy was associated with death at earlier ages and limited
AD pathology. Pathologically conﬁrmed AD was not as-
sociated with extensive coronary atherosclerosis. Surpris-
ingly, it was associated with mitral and aortic valve dam-
age and damage to the ventricular myocardium.
ACKNOWLEDGMENTS
We thank the study subjects and their families who
made the project possible. Hai Huang MD and Yi-Ping
Pan MD were responsible for data abstraction. Finan-
cial support for the study was provided by Grants P50
AG05128 and R01AG07198 from the National Institute
on Aging (USA), Glaxo Smith-Kline, and numerous small
donations from patients and family members to the
Joseph and Kathleen Bryan Alzheimer Disease Research
Center.
REFERENCES
[1] Evans DA, Funkenstein HH, Albert MS, et al. Preva-
lence of Alzheimer’s disease in a community popu-
lation of older persons. Higher than previously re-
ported. JAMA. 1989;262(18):2551–2556.
[2] Silver MH, Jilinskaia E, Perls TT. Cognitive func-
tional status of age-conﬁrmed centenarians in a
population-based study. JG e r o n t o lBP s y c h o lS c iS o c
Sci. 2001;56(3):P134–P140.
[3] Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk
of dementia and Alzheimer’s disease The impact
of mortality on risk estimates in the Framingham
study. Neurology. 1997;49(6):1498–1504.
[4] Strittmatter WJ, Saunders AM, Schmechel D, et al.
Apolipoprotein E: high-avidity binding to beta-
amyloid and increased frequency of type 4 allele in
late-onset familial Alzheimer disease. Proc Nat Acad
Sci USA. 1993;90(5):1977–1981.
[5] Saunders AM, Strittmatter WJ, Schmechel D, et al.
Association of apolipoprotein E allele epsilon 4 with
late-onset familial and sporadic Alzheimer’s disease.
Neurology. 1993;43(8):1467–1472.
[6] Corder EH, Saunders AM, Strittmatter WJ, et al.
Gene dose of apolipoprotein E type 4 allele and the
risk of Alzheimer’s disease in late onset families. Sci-
ence. 1993;261(5123):921–923.
[7] Lucotte G, Visvikis S, Leininger-Muler B, et al. Asso-
ciation of apolipoprotein E allele epsilon 4 with late-
onset sporadic Alzheimer’s disease. Am J Med Genet.
1994;54(3):286–288.
[8] Lucotte G, Aouizerate A, Gerard N, Turpin JC,
Landais P. Allele doses of apolipoprotein E type ep-
silon 4 in sporadic late-onset Alzheimer’s disease.
Am J Med Genet. 1995;60(6):566–569.
[9] Lucotte G, Turpin JC, Landais P. Apolipoprotein E-
epsilon 4 allele doses in late-onset Alzheimer’s dis-
ease. Ann Neurol. 1994;36(4):681–682.
[10] Schmechel DE, Saunders AM, Strittmatter WJ, et al.
Increased amyloid beta-peptide deposition in cere-
bral cortex as a consequence of apolipoprotein E
genotype in late-onset Alzheimer disease. Proc Nat
Acad Sci USA. 1993;90(20):9649–9653.
[11] Cumming AM,RobertsonFW.Polymorphism atthe
apoprotein-E locus in relation to risk of coronary
disease. Clin Genet. 1984;25(4):310–313.
[12] Davignon J, Gregg RE, Sing CF. Apolipoprotein E
polymorphism and atherosclerosis. Arteriosclerosis.
1988;8(1):1–21.
[13] Laakso M, Kesaniemi A, Kervinen K, Jauhiainen
M, Pyorala K. Relation of coronary heart dis-
ease and apolipoprotein E phenotype in pa-
tients with non-insulin dependent diabetes. BMJ.
1991;303(6811):1159–1162.
[14] van Bockxmeer FM, Mamotte CD. Apolipoprotein
epsilon4homozygosityinyoungmenwithcoronary
heart disease. Lancet. 1992;340(8824):879–880.
[15] Eichner JE, Kuller LH, Orchard TJ, et al. Relation
of apolipoprotein E phenotype to myocardial infarc-
tion and mortality from coronary artery disease. Am
JC a r d i o l . 1993;71(2):160–165.
[16] Stengard JH, Zerba KE, Pekkanen J, Ehnholm C,
Nissinen A, Sing CF. Apolipoprotein E polymor-
phism predicts death from coronary heart disease in
a longitudinal study of elderly Finnish men. Circula-
tion. 1995;91(2):265–269.
[17] Hallman DM, Boerwinkle E, Saha N, et al. The
apolipoprotein E polymorphism: a comparison of
allele frequencies and eﬀects in nine populations.
Am J Hum Genet. 1991;49(2):338–349.
[18] Wilson PW. Established risk factors and coronary
artery disease: the Framingham study. Am J Hyper-
tens. 1994;7(pt 2):7S–12S.
[ 1 9 ] G e r d e sL U ,G e r d e sC ,K e r v i n e nK ,e ta l .T h e
apolipoprotein epsilon 4 allele determines progno-
sis and the eﬀect on prognosis of simvastatin in sur-
vivors of myocardial infarction: a substudy of the
Scandinaviansimvastatinsurvivalstudy.Circulation.
2000;101(12):1366–1371.
[20] Slooter AJ, Tang MX, van Duijn CM, et al.
Apolipoprotein E epsilon 4 and the risk of demen-
tia with stroke. A population-based investigation.
JAMA. 1997;277(10):818–821.
[21] Goldstein LB, Vitek MP, Dawson H, Bullman S. Ex-
pression of the apolipoprotein E gene does not aﬀect
motor recovery after sensorimotor cortex injury in
the mouse. Neuroscience. 2000;99(4):705–710.
[2 2 ] P as q ui e rF ,H e n o nH ,L ey sD .R i s kfact o r san dm ec h -
anisms of post-stroke dementia. Rev Neurol (Paris).
1999;155(9):749–753.
[23] Ervin JF, Pannell C, Szymanski M, Welsh-Bohmer
K, Schmechel DE, Hulette CM. Vascular smooth
muscle actin is reduced in Alzheimer disease brain:2005:2 (2005) Heart Disease and AD 197
a quantitative analysis. J Neuropathol Exp Neurol.
2004;63(7):735–741.
[24] Corder EH, Basun H, Fratiglioni L, et al. Inherited
frailty. ApoE alleles determine survival after a diag-
nosis of heart disease or stroke at ages 85+. Ann N Y
Acad Sci. 2000;908:295–298.
[25] Schachter F, Faure-Delanef L, Guenot F, et al. Ge-
netic associations with human longevity at the
APOE and ACE loci. Nat Genet. 1994;6(1):29–32.
[26] Aronson MK, Ooi WL, Morgenstern H, et al.
Women, myocardial infarction, and dementia in the
very old. Neurology. 1990;40(7):1102–1106.
[27] Breteler MM, Claus JJ, Grobbee DE, Hofman A.
Cardiovascular disease and distribution of cogni-
tive function in elderly people: the Rotterdam study.
BMJ. 1994;308(6944):1604–1608.
[28] Sparks DL, Scheﬀ SW, Liu H, Landers TM,
Coyne CM, Hunsaker JC 3rd. Increased inci-
dence of neuroﬁbrillary tangles (NFT) in non-
demented individuals with hypertension. JN e u r o l
Sci. 1995;131(2):162–169.
[ 2 9 ]P r i n c eM ,C u l l e nM ,M a n nA .R i s kf a c t o r sf o r
Alzheimer’s disease and dementia: a case-control
study based on the MRC elderly hypertension trial.
Neurology. 1994;44(1):97–104.
[30] Launer LJ, Masaki K, Petrovitch H, Foley D, Hav-
lik RJ. The association between midlife blood
pressure levels and late-life cognitive func-
tion. The Honolulu-Asia aging study. JAMA.
1995;274(23):1846–1851.
[31] Skoog I, Lernfelt B, Landahl S, et al. 15-year longitu-
dinal study of blood pressure and dementia. Lancet.
1996;347(9009):1141–1145.
[32] Guo Z, Viitanen M, Winblad B, Fratiglioni L. Low
blood pressure and incidence of dementia in a very
old sample: dependent on initial cognition. JA m
Geriatr Soc. 1999;47(6):723–726.
[33] Hofman A, Ott A, Breteler MM, et al. Atheroscle-
rosis, apolipoprotein E, and prevalence of demen-
tia and Alzheimer’s disease in the Rotterdam study.
Lancet. 1997;349(9046):151–154.
[34] Lass P, Buscombe JR, Harber M, Davenport A, Hil-
son AJ. Cognitive impairment in patients with renal
failure is associated with multiple-infarct dementia.
Clin Nucl Med. 1999;24(8):561–565.
[35] Irina A, Seppo H, Arto M, Paavo R Sr, Hilkka S. β-
amyloid load is not inﬂuenced by the severity of car-
diovascular disease in aged and demented patients.
Stroke. 1999;30:613–618.
[36] Hulette CM, Welsh-Bohmer KA, Crain B, Szyman-
ski MH, Sinclaire NO, Roses AD. Rapid brain au-
topsy. The Joseph and Kathleen Bryan Alzheimer’s
Disease Research Center experience. Arch Pathol Lab
Med. 1997;121(6):615–618.
[37] Brown P, Wolﬀ A, Gajdusek DC. A simple and
eﬀective method for inactivating virus infectiv-
ity in formalin-ﬁxed tissue samples from pa-
tients with Creutzfeldt-Jakob disease. Neurology.
1990;40(6):887–890.
[38] Centers for Disease Control. Agent summary state-
ment for human immunodeﬁciency virus and re-
port on laboratory-acquired infection with human
immunodeﬁciency virus. MMWR. 1988;37:S5.
[39] Manton KG, Woodbury MA, Tolley HD. Statistical
Applications Using Fuzzy Sets. New York, NY:John
Wiley & Sons; 1994.
[40] Manton KG, Stallard E, Corder LS. The dynamics of
dimensions of age-related disability 1982 to 1994 in
the US elderly population. JG e r o n t o lAB i o lS c iM e d
Sci. 1998;53(1):B59–B70.
[41] Akaike H. Information theory and an extension of
the maximum likelihood principle. In: Proc 2nd In-
ternational Symposium on Information Theory.B u -
dapest, Hungary:Akademiai Kiado; 1973:267–281.
[42] Hulette CM, Welsh-Bohmer KA, Murray MG, Saun-
ders AM, Mash DC, McIntyre LM. Neuropathologi-
cal and neuropsychological changes in “normal” ag-
ing: evidence for preclinical Alzheimer disease in
cognitively normal individuals. JN e u r o p a t h o lE x p
Neurol. 1998;57(12):1168–1174.
[43] Kosunen O, Talasniemi S, Lehtovirta M, et al. Re-
lation of coronary atherosclerosis and apolipopro-
tein E genotypes in Alzheimer patients. Stroke.
1995;26(5):743–748.
[ 4 4 ]M e y e rJ S ,R a u c hG ,R a u c hR A ,H a q u eA .R i s k
factors for cerebral hypoperfusion, mild cogni-
tive impairment, and dementia. Neurobiol Aging.
2000;21(2):161–169.
[45] Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscov-
ick DS. Association of aortic-valve sclerosis with car-
diovascular mortality and morbidity in the elderly.
NE n g lJM e d . 1999;341(3):142–147.
[46] Stengard JH, Pekkanen J, Sulkava R, Ehnholm C,
Erkinjuntti T, Nissinen A. Apolipoprotein E poly-
morphism, Alzheimer’s disease and vascular demen-
tia among elderly Finnish men. Acta Neurol Scand.
1995;92(4):297–298.